Last reviewed · How we verify
Vogalene (METOPIMAZINE)
Vogalene (generic name: METOPIMAZINE) is a metopimazine drug. It is currently in Phase 2 development.
Metopimazine works by blocking the D(2) dopamine receptor, which can help regulate various physiological processes.
Vogalene, also known as metopimazine, is a small molecule drug that targets the D(2) dopamine receptor. It is a member of the metopimazine drug class, but its commercial status and approved indications are unknown. The drug has a half-life of 4.0 hours and bioavailability of 20%. As a pharmaceutical professional, it is essential to consider its potential safety implications, including its effects on the dopamine system. Further research is needed to determine its full potential and limitations.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | METOPIMAZINE |
|---|---|
| Drug class | metopimazine |
| Target | D(2) dopamine receptor, D(3) dopamine receptor, Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain is like a city with many different streets. Dopamine is like a messenger that helps different parts of the city communicate with each other. By blocking the D(2) dopamine receptor, metopimazine can help slow down or speed up the flow of this messenger, depending on the situation.
Approved indications
Common side effects
- Acute kidney injury
- Febrile bone marrow aplasia
- Drug reaction with eosinophilia and systemic symptoms
- Cholestasis
- Coma
- Poisoning deliberate
- Hyperkalaemia
- Pancreatitis acute
- Hepatocellular injury
- Analgesic drug level increased
- Hepatitis
- Thrombocytopenia
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist (PHASE2)
- A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vogalene CI brief — competitive landscape report
- Vogalene updates RSS · CI watch RSS
Frequently asked questions about Vogalene
What is Vogalene?
How does Vogalene work?
What is the generic name of Vogalene?
What drug class is Vogalene in?
What development phase is Vogalene in?
What are the side effects of Vogalene?
What does Vogalene target?
Related
- Drug class: All metopimazine drugs
- Target: All drugs targeting D(2) dopamine receptor, D(3) dopamine receptor, Histamine H1 receptor
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing